Julie is a scientist, C-level executive, and entrepreneur with more than 30 years of experience advancing MedTech innovations through FDA clearance and GMP manufacturing across medical devices, digital health, and in vitro diagnostics. She brings a practical combination of scientific depth, operating experience, product development strategy, and commercialization insight to her work with innovators and early-stage companies. Julie has led R&D efforts at major health technology companies, including Abbott, Beckman Coulter, and Agilent. She also founded and grew a life science service company from launch to $10 million before a successful exit, giving her firsthand experience building and scaling a business in the life sciences sector. Her expertise includes developing and executing FDA pathways, assessing MedTech technology readiness, supporting investor diligence, and guiding companies through early-stage activities such as need identification, value proposition development, business model design, and product-market fit. She is especially interested in technologies, products, and services that make healthcare more accessible and shift care into the home. Julie was a member of the $2 billion RADx Tech NIBIB initiative, which helped create U.S. manufacturing capacity for COVID-19 tests. In that role, she led multiple company teams through successful FDA authorization and manufacturing scale-up for new diagnostics in record-breaking time. Her background also includes leading R&D teams through successful 510(k), de novo, Class I, II, and III FDA diagnostics product development across technologies involving nucleic acids, proteins, cells, viruses, bacteria, and fungi. She has supported digital health companies focused on mental health and evidence-based behavior-modifying apps, developed FDA-cleared clinical lab diagnostic platforms and reagents with significant global sales, and led ISO-9001 and ISO-13485 certification efforts for international medical device technology providers.